In a landmark study, many patients with mismatch repair–deficient (dMMR, also known as MMRd) cancers were effectively treated with immunotherapy alone, without surgery, chemotherapy, or radiation. 100% of patients with dMMR rectal cancer, and around

The type of mutations, or genetic variants, tracked in circulating tumor DNA (ctDNA)–based minimal residual disease (MRD) testing matters. Haystack MRD™ prioritizes truncal somatic mutations—those mutations that are present at the initial formation of a

One of the most critical differentiators among minimal residual disease (MRD) tests is whether they are tumor-informed—that is, using information from a patient’s tumor sample to design a personalized test—or whether they are tumor-naive, using

An enduring challenge in cancer management is the accurate identification of patients who harbor any remaining cancer cells—or minimal residual disease (MRD)—following curative-intent treatment such as surgery to remove a tumor. These patients require additional